Cover Image

Severe nonanaphylactic allergic reaction to the Pfizer-BioNTech COVID-19 vaccine

Saved in:

Bibliographic Details
Main Authors:	Hayden Doughty, BS (Author), Dorothea Barton, MD (Author)
Format:	Book
Published:	Elsevier, 2022-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Erythematous reaction of the BCG site to Pfizer‐BioNTech COVID‐19 vaccine
by: Yuta Ito, et al.
Published: (2023)

Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine
by: Olivia G. Cohen, et al.
Published: (2021)

Focal segmental glomerulosclerosis following the Pfizer-BioNTech COVID-19 vaccine
by: Cho A Lim, et al.
Published: (2022)

Palmoplantar lichenoid drug eruption following the administration of Pfizer-BioNTech COVID-19 vaccine
by: Giovanni Paolino, MD, PhD, et al.
Published: (2022)

Side Effects of Pfizer-BioNTech COVID-19 Vaccine among medical staff
by: Wail Sadeq, et al.
Published: (2022)

FDA approval of Pfizer-BioNTech: Evaluating the significance of mRNA vaccine approval
by: Syed Abdullah Monawwer, et al.
Published: (2021)

A Rare Cutaneous Manifestation: Leukocytoclastic Vasculitis after Pfizer-BioNTech COVID-19 Vaccination
by: Yaritza Serrano Gomez, et al.
Published: (2022)

A Survey of the Side Effects of Pfizer/BioNTech COVID-19 Vaccine among Vaccinated Adults in Iraq
by: Abubakir Saleh, et al.
Published: (2023)

Systemic drug-related intertriginous and flexural exanthema induced by the Pfizer-BioNTech COVID-19 vaccine: A report of 2 cases
by: Josephine Hai, BS, et al.
Published: (2021)

Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases
by: Massimo Petruzzi, et al.
Published: (2022)

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer-BioNTech) COVID‐19 vaccination
by: Akihiro Matsubara, et al.
Published: (2021)

Evaluating Pharmacists’ Pharmacological Knowledge and Views Regarding Pfizer-BioNTech COVID-19 Vaccine in Saudi Arabia
by: Alorfi N, et al.
Published: (2022)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
by: Yohhei Hamada
Published: (2021)

Two cases with generalised bullous cutaneous reactions after COVID‐19 mRNA vaccine Moderna (Spikevax®) and Pfizer-BioNTech (Comirnaty®)
by: Charlotte E. Rinnooy Kan, et al.
Published: (2024)

Effectiveness of Pfizer/BioNTech and Sinopharm COVID-19 vaccines in reducing hospital admissions in prince Hamza hospital, Jordan
by: Hafez Al-Momani, et al.
Published: (2022)

Erythema multiforme reactions after Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccination: A case series
by: Elif Karatas, MD, et al.
Published: (2023)

The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence
by: Luis Rosero-Bixby
Published: (2022)

Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review
by: Lia Reynolds, et al.
Published: (2023)

Recurrent giant cellulitis-like sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine
by: Penelope Hirt, et al.
Published: (2023)

Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
by: Rumiko Shimazawa, et al.
Published: (2021)

Recurrent erythema nodosum after the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
by: Xiaotian Wu, MBBS, MRCP, MMed, et al.
Published: (2022)

Diagnosis of Angioimmunoblastic T Cell Lymphoma After Receiving First Dose of Pfizer/BioNTech (BNT162b2) Vaccine: A Case Report
by: Jai Kumar Khatri MD, et al.
Published: (2024)

Linfadenopatía cervical y supraclavicular ipsilateral a la vacunación de refuerzo con Pfizer-BioNTech COVID-19
by: Mariana Checo, et al.
Published: (2022)

Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
by: Jose W. Ricardo, MD, et al.
Published: (2021)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence
by: Rujittika Mungmunpuntipantip, et al.
Published: (2022)

The effectiveness of single and two-dose Pfizer-BioNTech vaccine against SARS-COV-2: A real-world evidence from Saudi Arabia
by: Yasser Albogami, et al.
Published: (2023)

A case of extensive alopecia areata following Pfizer‐BioNTech BNT162b2 mRNA COVID‐19 vaccine with favorable outcome
by: Yoshihiro Matsuda, et al.
Published: (2023)

Childhood primary angiitis of the central nervous system following COVID-19 vaccination (BNT162b2/Pfizer-BioNtech): A case report
by: Toshiki Ariyoshi, et al.
Published: (2023)

Effectiveness of the Pfizer-BioNTech Vaccine against COVID-19-Associated Hospitalizations among Lebanese Adults ≥75 Years Old-Lebanon, April-May 2021
by: Zeina Farah, et al.
Published: (2023)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Author's reply to correspondence
by: Giancarlo Ripabelli, et al.
Published: (2023)

Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia
by: Jenan Ahmed Al-Matouq, et al.
Published: (2022)

Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis
by: Patrick DMC. Katoto, et al.
Published: (2023)

Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis
by: Patrick D. M. C. Katoto, et al.
Published: (2022)

Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses
by: Patrick DMC Katoto, et al.
Published: (2023)

Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile
by: Diego A. Díaz-Dinamarca, et al.
Published: (2023)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Results from an active pharmacovigilance study in central Italy
by: Giancarlo Ripabelli, et al.
Published: (2022)

BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
by: Shir Azrielant, et al.
Published: (2024)

Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19 - A Prospective Cohort Study
by: Morales-Núñez JJ, et al.
Published: (2022)

Pfizer: The miracle vaccine for COVID-19?
by: A.A. Badiani, et al.
Published: (2020)

Vesiculobullous Lyme disease: A case series
by: Hayden Doughty, BS, et al.
Published: (2022)